33 results on '"Scher, Jose U."'
Search Results
2. Psoriatic Arthritis
- Author
-
Malik, Fardina, Haberman, Rebecca, Scher, Jose U., and Efthimiou, Petros, editor
- Published
- 2020
- Full Text
- View/download PDF
3. Microbial-derived antigens and metabolites in spondyloarthritis
- Author
-
Yang, Katharine Lu, Lejeune, Alannah, Chang, Gregory, Scher, Jose U., and Koralov, Sergei B.
- Published
- 2021
- Full Text
- View/download PDF
4. Microbiome and Microbiota in Rheumatic Disease
- Author
-
Attur, Malavikalakshmi M., Scher, Jose U., and Espinoza, Luis R., editor
- Published
- 2019
- Full Text
- View/download PDF
5. Use of the Bath Ankylosing Spondylitis Disease Activity Index in Patients With Psoriatic Arthritis With and Without Axial Disease.
- Author
-
Reddy, Soumya M., Xue, Katie, Husni, M. Elaine, Scher, Jose U., Stephens-Shields, Alisa J., Goel, Niti, Koplin, Joelle, Craig, Ethan T., Walsh, Jessica A., and Ogdie, Alexis
- Abstract
Objective. To evaluate whether the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a responsive instrument in psoriatic arthritis (PsA) and whether it differentiates between axial and peripheral disease activity in PsA. Methods. Individuals with PsA initiating therapy in a longitudinal cohort study based in the United States were included. Axial PsA (axPsA), most often also associated with peripheral disease, was defined as ful- fillment of the Assessment of Spondyloarthritis international Society axial spondyloarthritis classification criteria or presence of axial disease imaging features. Baseline BASDAI, individual BASDAI items, patient global assessment, patient pain, and Routine Assessment of Patient Index Data 3, and score changes following therapy initiation were descriptively reported. Standardized response means (SRMs) were calculated as the mean change divided by the SD of the change. Results. The mean (SD) baseline BASDAI score at the time of therapy initiation was 5.0 (2.2) among those with axPsA (n = 40) and 4.8 (2.0) among those with peripheral-only disease (n = 79). There was no significant difference in patient-reported outcome scores between the groups. The mean change for BASDAI was similar among axial vs peripheral disease (-0.75 vs -0.83). SRMs were similar across axial vs peripheral disease for BASDAI (-0.37 vs -0.44) and the individual BASDAI items. Conclusion. BASDAI has reasonable responsiveness in PsA but does not differentiate between axPsA and peripheral PsA. (ClinicalTrials.gov: NCT03378336) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN
- Author
-
Bell, Stacie, Merola, Joseph F., Webster, Dan E., Pennington, Stephen R., Liao, Wilson, Ogdie, Alexis, FitzGerald, Oliver, Ritchlin, Christopher, and Scher, Jose U.
- Published
- 2020
- Full Text
- View/download PDF
7. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study
- Author
-
Hudesman, David P., Chakravarty, Soumya D., Emond, Bruno, Ellis, Lorie A., Lefebvre, Patrick, Sadik, Kay, and Scher, Jose U.
- Published
- 2020
- Full Text
- View/download PDF
8. Responsiveness and Minimum Clinically Important Difference in Patient‐Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study.
- Author
-
Karmacharya, Paras, Stull, Courtney, Stephens‐Shields, Alisa, Husni, M. Elaine, Scher, Jose U., Craig, Ethan, Fitzsimmons, Robert, Reddy, Soumya M., Magrey, Marina N., Ogdie, Alexis, and Walsh, Jessica A.
- Subjects
PATIENT reported outcome measures ,COHORT analysis ,PSORIATIC arthritis ,LONGITUDINAL method ,ANKYLOSING spondylitis ,JOINT diseases - Abstract
Objective: To determine the responsiveness to therapy and minimum clinically important improvement (MCII) for patient‐reported outcome measures in psoriatic arthritis (PsA) and to examine the impact of baseline disease activity on the ability to demonstrate change. Methods: A longitudinal cohort study was performed within the PsA Research Consortium. Patients completed several patient‐reported outcomes, including the Routine Assessment of Patient Index Data, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Psoriatic Arthritis Impact of Disease 12‐item (PsAID12) questionnaire, and others. The mean change in the scores between visits and standardized response means (SRMs) were calculated. The MCII was calculated as the mean change in score among patients who reported minimal improvement. SRMs and MCIIs were compared among subgroups with moderate to highly active PsA and those with lower disease activity. Results: Among 171 patients, 266 therapy courses were included. The mean ± SD age was 51 ± 13.8 years, 53% were female, and the mean swollen and tender joint counts were 3 and 6, respectively, at baseline. SRMs and MCII for all measures were small to moderate, although greater among those with higher baseline disease activity. BASDAI had the best SRM overall and for less active PsA, and the clinical Disease Activity of PsA (cDAPSA) and PsAID12 were best for those with higher disease activity. Conclusion: SRMs and MCII were relatively small in this real‐world population, particularly among those with lower disease activity at baseline. BASDAI, cDAPSA, and PsAID12 had good sensitivity to change, but selection for use in trials should consider the baseline disease activity of patients to be enrolled. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry
- Author
-
Kavanaugh, Arthur, Papp, Kim, Gottlieb, Alice B., de Jong, Elke M. G. J., Chakravarty, Soumya D., Kafka, Shelly, Langholff, Wayne, Farahi, Kamyar, Srivastava, Bhaskar, and Scher, Jose U.
- Published
- 2018
- Full Text
- View/download PDF
10. Spondyloarthritis and the Microbiome: New Insights From an Ancient Hypothesis
- Author
-
Manasson, Julia and Scher, Jose U.
- Published
- 2015
- Full Text
- View/download PDF
11. Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.
- Author
-
Nguyen, Tien, Churchill, Melvin, Levin, Robert, Valenzuela, Guillermo, Merola, Joseph F, Ogdie, Alexis, Orbai, Ana-Maria, Scher, Jose U, Kavanaugh, Arthur, Kianifard, Farid, Rollins, Chauncy, Calheiros, Renato, and Chambenoit, Olivier
- Subjects
BIOTHERAPY ,THERAPEUTIC use of monoclonal antibodies ,PSORIATIC arthritis ,PSORIASIS ,RESEARCH ,RESEARCH methodology ,EVALUATION research ,ANTIRHEUMATIC agents ,TREATMENT effectiveness ,COMPARATIVE studies ,RANDOMIZED controlled trials ,BLIND experiment - Abstract
Objective: To evaluate secukinumab (SEC) 300 mg and 150 mg vs placebo in a United States-only population of biologic-naïve patients with psoriatic arthritis (PsA).Methods: CHOICE was a double-blind, randomized controlled trial conducted in the US. Biologic-naïve patients with PsA and psoriasis (PsO) were randomized 2:2:1 to SEC 300 mg (n = 103), SEC 150 mg (n = 103), or placebo (n = 52). The primary objective was to show superiority of SEC 300 mg vs placebo in American College of Rheumatology 20% (ACR20) response at week 16. Additional objectives included the effect of SEC on dactylitis, enthesitis, PsO, and safety.Results: ACR20 response rates at week 16 were higher with SEC 300 mg than with placebo (51.5% vs 23.1%; odds ratio 3.51 [95% CI 1.65-7.45]; P = 0.001). SEC 300 mg also led to greater ACR50/70 responses and improvements in other variables vs placebo. Responses were generally sustained over time. Patients with inadequate response to SEC 150 mg at weeks 16, 28, or 40 who received dose escalation to 300 mg experienced improved clinical response after uptitration. The most common adverse events were upper respiratory tract infections and diarrhea. No inflammatory bowel disease was reported or new safety signals observed.Conclusion: SEC 300 mg led to rapid and significant improvements over placebo in symptoms of PsA in this heavier population of US-only, biologic-naïve patients. Findings were consistent with previous studies and suggest that SEC 300 mg is a safe and efficacious first-line biologic treatment for patients with PsA. [ClinicalTrials.gov: NCT02798211]. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
12. Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.
- Author
-
Stober, Carmel, McInnes, Iain B., Raychaudhuri, Soumya, Mease, Philip J., Pennington, Stephen R., Scher, Jose U., Chandran, Vinod, Armstrong, April W., de Wit, Maarten, Cauli, Alberto, Jadon, Deepak R., Löve, Thorvardur J., Ogdie, Alexis, O'Sullivan, Denis, van Mens, Leonieke J. J., Ritchlin, Christopher T., FitzGerald, Oliver, and Wit, Maarten de
- Subjects
PSORIATIC arthritis ,PSORIASIS ,ASSOCIATIONS, institutions, etc. ,PILOT projects ,RESEARCH ,RHEUMATOLOGY ,RESEARCH methodology ,EVALUATION research ,COMPARATIVE studies - Abstract
At the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a number of project updates, including a pilot investigator-initiated study to evaluate liquid and tissue biomarkers associated with axial involvement in psoriatic arthritis (PsA). The GRAPPA-CRN session updated progress made with 3 parallel international research initiatives based on 3 previously defined unmet needs in PsA. The Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States (HIPPOCRATES) is a European research consortium formed to address unmet clinical needs in PsA. The Preventing Arthritis in a multicenter Psoriasis At-Risk Population (PAMPA) is a US-based organization that has defined consensus terminology for preclinical phases of PsA and is interested in the transition process from psoriasis to PsA. An overview of the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) program 2.0, a consortium including GRAPPA-CRN members that addressed these 3 unmet needs in PsA, was also presented. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis.
- Author
-
Lubberts, Erik, Scher, Jose U., and FitzGerald, Oliver
- Abstract
The second basic science session at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting focused on 2 recent publications that have increased our understanding of the pathogenesis of psoriatic arthritis (PsA). Data from the first publication, presented by Prof. Erik Lubberts, showed that interleukin (IL)-17A is produced by CD4+ and not CD8+ T cells in PsA synovial fluid following T cell receptor activation. These findings contrast with previously published data, which had suggested that CD8+ T cells are a prominent source of IL-17A. In further experiments, they showed that when CD8+ T cells were stimulated with paramethoxyamphetamine/ionomycin, relatively high levels of IL-17A were detected. Prof. Jose Scher presented work on the role of the microbiome in PsA and more specifically, on pharmacomicrobiomics. He demonstrated the baseline collection of genomes and genes from the microbiota community (the metagenome) can be used as predictor for future treatment response in early rheumatoid arthritis and also likely in PsA. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Does biologic therapy impact the development of PsA among patients with psoriasis?
- Author
-
Meer, Elana, Merola, Joseph F., Fitzsimmons, Robert, Jon Love, Thorvardur, Shiyu Wang, Shin, Daniel, Yong Chen, Sharon Xie, Hyon Choi, Yuqing Zhang, Scher, Jose U., Ritchlin, C. T., Gelfand, Joel M., Ogdie, Alexis, Love, Thorvardur Jon, Wang, Shiyu, Chen, Yong, Xie, Sharon, Choi, Hyon, and Zhang, Yuqing
- Subjects
BIOTHERAPY ,PSORIASIS treatment ,PSORIATIC arthritis ,RESEARCH ,PHOTOTHERAPY ,ORAL drug administration ,RESEARCH methodology ,RETROSPECTIVE studies ,DISEASE incidence ,EVALUATION research ,COMPARATIVE studies ,DERMATOLOGIC agents - Abstract
Objective: To examine the association of biologic therapy use for psoriasis with incident psoriatic arthritis (PsA) diagnosis.Methods: A retrospective cohort study was conducted in the OptumInsights Electronic Health Record Database between 2006 and 2017 among patients with psoriasis between the ages of 16 and 90 initiating a therapy for psoriasis (oral, biologic or phototherapy). The incidence of PsA was calculated within each therapy group. Multivariable Cox models were used to calculate the HR for biologic versus oral or phototherapy using biologics as a time-varying exposure and next in a propensity score-matched cohort.Results: Among 1 93 709 patients with psoriasis without PsA, 14 569 biologic and 20 321 cumulative oral therapy and phototherapy initiations were identified. Mean age was lower among biologic initiators compared with oral/phototherapy initiators (45.9 vs 49.8). The incidence of PsA regardless of therapy exposure was 9.75 per 1000 person-years compared with 77.26 among biologic users, 61.99 among oral therapy users, 26.11 among phototherapy users and 5.85 among those without a prescription for one of the target therapies. Using a multivariable adjustment approach with time-varying exposure, adjusted HR (95% CI) for biologic users was 4.48 (4.23 to 4.75) compared with oral or phototherapy users. After propensity score matching, the HR (95% CI) was 2.14 (2.00 to 2.28).Conclusions: In this retrospective cohort study, biologic use was associated with the development of PsA among patients with psoriasis. This may be related to confounding by indication and protopathic bias. Prospective studies are needed to address this important question. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
15. Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis.
- Author
-
Scher, Jose U., Ogdie, Alexis, Merola, Joseph F., and Ritchlin, Christopher
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *PSORIATIC arthritis , *DRUG efficacy , *COMBINATION drug therapy , *TREATMENT effectiveness , *IMMUNOLOGICAL adjuvants , *DISEASE remission , *DRUG administration , *DRUG dosage - Abstract
The article discusses developments in the treatment of psoriatic arthritis (PsA), particularly the adoption of combination immunomodulatory therapies. Also cited are the use of tumor necrosis factor inhibitors (TNFi) to identify the signs and symptoms of PsA, rheumatoid arthritis (RA), and psoriasis, and some TNFis like etanercept, adalimumab, and infliximab.
- Published
- 2021
- Full Text
- View/download PDF
16. Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting.
- Author
-
Mease, Philip J., Calabrese, Leonard H., Duffin, Kristina Callis, Haberman, Rebecca H., Firmino, Rodrigo, Scher, Jose U., Schick, Lori, Winthrop, Kevin, and Merola, Joseph F.
- Subjects
PSORIASIS ,SKIN diseases ,PSORIATIC arthritis ,COVID-19 pandemic ,TELEMEDICINE - Abstract
The coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) pandemic has affected the healthcare system on a global scale, and we utilized the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 annual meeting to examine how COVID-19 might affect patients with psoriatic disease (PsD) and the clinicians who care for them. Pressing issues and concerns identified included whether having psoriasis increased the risk of acquiring COVID-19, vaccine safety, and the acceptability of telehealth. The general message from rheumatologists, dermatologists, infectious disease specialists, and patient research partners was that data did not suggest that having PsD or its treatment significantly increased risk of infection or more severe disease course, and that the telehealth experience was a success overall. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.
- Author
-
Stober, Carmel, Jadon, Deepak R., Armstrong, April W., Chandran, Vinod, de Wit, Maarten, Helliwell, Philip S., Mease, Philip, Ogdie, Alexis, O'Sullivan, Denis, Pennington, Stephen R., Löve, Thorvardur, Cauli, Alberto, van Mens, Leonieke, Waxman, Robin, Scher, Jose U., Barton, Anne, Ritchlin, Christopher T., and FitzGerald, Oliver
- Subjects
BIOMARKERS ,COOPERATIVE research ,PSORIASIS ,SKIN diseases ,MEDICAL care - Abstract
At the 2020 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a pilot investigator-initiated study protocol to test electronic case report forms (eCRFs) and proposed Standardized Operating Procedures (SOPs) to evaluate biomarkers of psoriatic arthritis (PsA) associated with axial disease. The progress on 3 studies was also presented: BioDAM PsA (Biomarkers as Predictors of structural DAMage in PsA; to validate soluble biomarkers as predictors of structural damage in PsA), PreventPsA (examining the development of PsA and risk factors among patients with psoriasis and no arthritis), and PredictORPsA (Predicting Treatment respOnse in patients with eaRly PsA; in collaboration with Pfizer using samples from the Oral Psoriatic Arthritis TriaL [OPAL], to identify biomarkers of treatment response). GRAPPA-CRN funding partnerships and applications are also underway with both the Innovative Medicines Initiative (IMI) in Europe and Accelerating Medicines Partnerships (AMP) 2.0 in the USA, and the progress of these applications and associated objectives were presented. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
- Author
-
Gelfand, Joel M., Armstrong, April W., Bell, Stacie, Anesi, George L., Blauvelt, Andrew, Calabrese, Cassandra, Dommasch, Erica D., Feldman, Steven R., Gladman, Dafna, Kircik, Leon, Lebwohl, Mark, Lo Re III, Vincent, Martin, George, Merola, Joseph F., Scher, Jose U., Schwartzman, Sergio, Treat, James R., Van Voorhees, Abby S., Ellebrecht, Christoph T., and Fenner, Justine
- Abstract
Objective: To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic.Study Design: The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted.Results: The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus.Limitations: The evidence behind many guidance statements is variable in quality and/or quantity.Conclusions: These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
19. A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health.
- Author
-
Wan, Marilyn T, Walsh, Jessica A, Craig, Ethan T, Husni, M Elaine, Scher, Jose U, Reddy, Soumya M, Leung, Ying-Ying, and Ogdie, Alexis
- Subjects
PSORIATIC arthritis ,STATISTICS ,RESEARCH methodology evaluation ,RESEARCH methodology ,HEALTH outcome assessment ,PHYSICAL fitness ,FUNCTIONAL assessment ,MULTITRAIT multimethod techniques ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,DATA analysis - Abstract
Objectives Physical function is a core outcome in PsA. We examined the construct validity and responsiveness of three commonly used instruments to assess physical function in PsA: HAQ disability index (HAQ-DI), MultiDimensional HAQ (MDHAQ) and the Patient-Reported Outcomes Measurement Information System (PROMIS
® ) Global-10. Methods Between 2016 and 2019, patients with PsA were enrolled in the Psoriatic Arthritis Research Consortium longitudinal cohort study in the USA. Correlations were calculated at baseline and among change scores using Spearman's correlation coefficient. Standardized response means were calculated. Agreement with the 20% improvement cut-off was used to determine the potential effect of using MDHAQ or the PROMIS Global-10 physical health (GPH) subscore in place of HAQ-DI when assessing the ACR20. Results A total of 274 patients were included in the analysis. The mean age of patients was 49 years and 51% were male. At baseline, the mean HAQ-DI was 0.6 (s. d. 0.6; range 0–3), the mean MDHAQ was 1.8 (s. d. 1.6; range 0–10) and the mean GPH T-score was 43.4 (s. d. 9.3; range 0–100). All three instruments were strongly correlated at baseline (rho 0.75–0.85). Change scores were moderately correlated (rho 0.42–0.71). Among therapy initiators, the mean change between two visits in HAQ-DI, MDHAQ and GPH was −0.1 (s. d. 0.4), −0.2 (s. d. 1.2) and 2.5 (s. d. 6.1), respectively. The standardized response means were 0.18, 0.16 and 0.41, respectively. Conclusion The three instruments tested are not directly interchangeable but have overall similar levels of responsiveness. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
20. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.
- Author
-
Gelfand, Joel M., Armstrong, April W., Bell, Stacie, Anesi, George L., Blauvelt, Andrew, Calabrese, Cassandra, Dommasch, Erica D., Feldman, Steve R., Gladman, Dafna, Kircik, Leon, Lebwohl, Mark, Lo Re III, Vincent, Martin, George, Merola, Joseph F., Scher, Jose U., Schwartzman, Sergio, Treat, James R., Van Voorhees, Abby S., Ellebrecht, Christoph T., and Fenner, Justine
- Abstract
Objective: To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic.Study Design: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.Results: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus.Limitations: The evidence behind many guidance statements is limited in quality.Conclusion: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
21. Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease.
- Author
-
Walsh, Jessica A., Wan, Marilyn T., Willinger, Christine, Husni, M. Elaine, Scher, Jose U., Reddy, Soumya M., and Ogdie, Alexis
- Subjects
PSORIATIC arthritis ,PSORIASIS ,CROSS-sectional method ,SEVERITY of illness index ,RESEARCH funding - Abstract
Objective: To examine the construct validity of Routine Assessment of Patient Index Data 3 (RAPID3) and Psoriatic Arthritis Impact of Disease (PsAID) in patients with psoriatic arthritis (PsA). In examining construct validity, we also addressed scores among subgroups with severe psoriasis, poly articular disease, enthesitis, and dactylitis, and evaluated influences of sociodemographic factors and comorbidities (contextual factors) on these patient-reported outcomes (PRO).Methods: Patients with PsA were enrolled in the Psoriatic Arthritis Research Consortium (PARC) between 2014 and 2016. PARC is a longitudinal observational cohort study conducted at 4 US institutions. In this cross-sectional study, construct validity was assessed by examining Spearman correlation coefficients for RAPID3 and PsAID with physician-reported disease activity measures and other PRO [e.g., Medical Outcomes Study Short Form-12 physical component summary/mental component summary (SF-12 PCS/MCS), Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-F)]. Contextual factors and disease subgroups were assessed in multivariable linear regression models with RAPID3 or PsAID12 as outcomes of interest and the hypothesized contextual factors as covariates.Results: Among 401 patients enrolled in PARC, 347 completed RAPID3 or PsAID12. Of these, most were white females with a mean age of 51.7 years (SD 14.02). RAPID3 and PsAID were highly correlated (r = 0.90). These measures were also correlated with the SF-12 PCS (r = -0.67) and FACIT-F (r = -0.77). Important contextual factors and disease subgroups included enthesitis, joint counts, education, insurance type, and depression.Conclusion: RAPID3 and PsAID12 have excellent construct validity in PsA and are strongly correlated despite differing items. Contextual factors (i.e., the presence of depression and obesity) should be considered when interpreting raw scores of the RAPID3 and PsAID12. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
22. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition.
- Author
-
Scher, Jose U., Ogdie, Alexis, Merola, Joseph F., and Ritchlin, Christopher
- Subjects
- *
PSORIATIC arthritis , *PSORIASIS , *SKIN diseases , *SYMPTOMS , *IMMUNOLOGIC diseases , *EVOLUTIONARY theories - Abstract
Psoriasis is one of the most common chronic inflammatory skin diseases, affecting 3% of the world's population, and approximately one-third of patients with psoriasis will eventually transition to having psoriatic arthritis (PsA). The evolution from cutaneous to synovio-entheseal inflammation in these patients presents an opportunity to investigate the critical events linked to arthritis development. The events responsible for progression to PsA are currently unclear. Genetic and clinical-demographic risk factors (most notably familial aggregation and psoriasis sub-phenotypes) provide relevant insights into the variables that promote transition. The specific underlying molecular and cellular mechanisms, however, remain poorly defined. Intriguingly, although targeting the IL-23-IL-17 axis substantially improves psoriasis outcomes, this strategy is not more effective than TNF inhibitors in improving musculoskeletal symptoms in PsA. Major unmet needs in the field of PsA include defining those patients with psoriasis at increased risk of developing arthritis, improving our understanding of the natural history of disease and characterizing the immune, environmental and molecular subclinical events preceding PsA onset. Improving our knowledge of this transition is essential for designing clinical trials with treatments that can delay, attenuate or even prevent the development of PsA in patients with psoriasis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Augmented Th17 Differentiation Leads to Cutaneous and Synovio‐Entheseal Inflammation in a Novel Model of Psoriatic Arthritis.
- Author
-
Yang, Lu, Fanok, Melania H., Mediero‐Munoz, Aranzazu, Fogli, Laura K., Corciulo, Carmen, Abdollahi, Shahla, Cronstein, Bruce N., Scher, Jose U., and Koralov, Sergei B.
- Subjects
ALLELES ,ANIMAL experimentation ,BIOLOGICAL models ,BONE marrow ,CELL differentiation ,CYTOKINES ,INTERLEUKINS ,MICE ,OSTEOPENIA ,PSORIATIC arthritis ,STEM cells ,T cells ,PHENOTYPES ,IN vivo studies ,CHEMICAL inhibitors - Abstract
Objective: To introduce a novel preclinical animal model of psoriatic arthritis (PsA) in R26Stat3C
stopfl/fl CD4Cre mice, and to investigate the role of Th17 cytokines in the disease pathogenesis. Methods: We characterized a novel murine model of Th17‐driven cutaneous and synovio‐entheseal disease directed by T cell–specific expression of a hyperactive Stat3 allele. By crossing R26Stat3Cstopfl/fl CD4Cre mice onto an interleukin‐22 (IL‐22)–knockout background or treating the mice with a neutralizing antibody against IL‐17, we interrogated how these Th17 cytokines could contribute to the pathogenesis of PsA. Results: R26Stat3Cstopfl/fl CD4Cre mice developed acanthosis, hyperkeratosis, and parakeratosis of the skin, as well as enthesitis/tendinitis and periarticular bone erosion in different joints, accompanied by osteopenia. T cell–specific expression of a hyperactive Stat3C allele was found to drive the augmented Th17 response in these animals. Careful characterization of the mouse bone marrow revealed an increase in osteoclast progenitor (OCP) and RANKL‐producing cells, which contributed to the osteopenia phenotype observed in the mutant animals. Abrogation of the Th17 cytokines IL‐17 or IL‐22 improved both the skin and bone phenotype in R26Stat3Cstopfl/fl CD4Cre mice, revealing a central role of Th17 cells in the regulation of OCP and RANKL expression on stromal cells. Conclusion: Perturbation of the IL‐23/Th17 axis instigates Th17‐mediated inflammation in R26Stat3Cstopfl/fl CD4Cre mice, leading to cutaneous and synovio‐entheseal inflammation and bone pathologic features highly reminiscent of human PsA. Both IL‐17A and IL‐22 produced by Th17 cells appear to play critical roles in promoting the cutaneous and musculoskeletal inflammation that characterizes PsA. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
24. GRAPPA 2020 Research Award Recipients.
- Author
-
Castillo, Rochelle L., Di Yan, Ashhurst, Anneliese S., Elliott, Ashley, Angioni, Maria Maddalena, Scher, Jose U., Naik, Shruti, Neimann, Andrea, Byrne, Scott N., Payne, Richard J., FitzGerald, Oliver, Pennington, Stephen R., Cauli, Alberto, Chandran, Vinod, and Yan, Di
- Subjects
PSORIATIC arthritis ,PSORIASIS ,DERMATOLOGY ,RHEUMATOLOGY ,AWARDS - Abstract
At the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting, a summary of the research conducted by the recipients of the 2020 GRAPPA Research Awards was presented by the awardees. The summary of the 4 presentations is provided here. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Review: Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases.
- Author
-
Scher, Jose U., Littman, Dan R., and Abramson, Steven B.
- Subjects
- *
GUT microbiome , *DIGESTION , *HOMEOSTASIS , *MICROBIOLOGICAL techniques , *PSORIATIC arthritis , *RHEUMATISM , *RHEUMATOID arthritis , *SPONDYLOARTHROPATHIES - Abstract
The article reviews various studies regarding intestinal microbiome and its role in prosiatic arthritis (PsA), rheumatoid arthritis (RA) and spondyloarthritides (SpA). Topics covered include the composition and function of microbiome, its prokaryotic nature, the hypothesis on toxemic factor and jejunoileal bypass surgery triggering arthritis syndrome. Conclusions indicated the need to explore microbiome aspects as to the dysbiotic process, microbial perturbation and immunosuppressive drugs.
- Published
- 2016
- Full Text
- View/download PDF
26. Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination.
- Author
-
Haberman, Rebecca H, Castillo, Rochelle, and Scher, Jose U
- Subjects
REMISSION induction ,BIOTHERAPY ,THERAPEUTIC use of monoclonal antibodies ,PSORIASIS ,PSORIATIC arthritis ,CYTOKINES ,PHYSICAL diagnosis ,COMBINATION drug therapy ,SKIN ,MONOCLONAL antibodies ,SEVERITY of illness index ,TREATMENT effectiveness ,ADALIMUMAB ,DISEASE remission ,JOINTS (Anatomy) - Abstract
In the article, the authors present a case of a 27-year-old woman with a history of psoriasis and psoriatic arthritis (PsA) who was presented to a centre due to active skin, joint and enthesial disease to discuss the induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination. She also has bilateral sacroiliitis and was treated with adalimumab.
- Published
- 2021
- Full Text
- View/download PDF
27. Reply.
- Author
-
Scher, Jose U., Reddy, Soumya, Ubeda, Carles, Neimann, Andrea, and Abramson, Steven B.
- Subjects
- *
T cells , *ACADEMIC medical centers , *GASTROINTESTINAL system , *MICROBIOLOGY , *PSORIATIC arthritis , *RESEARCH funding , *PSYCHOLOGICAL stress , *PHYSIOLOGY - Abstract
A response from the authors of the article "Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease," published in the 2015 issue is presented.
- Published
- 2015
- Full Text
- View/download PDF
28. Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease.
- Author
-
Scher, Jose U., Ubeda, Carles, Artacho, Alejandro, Attur, Mukundan, Isaac, Sandrine, Reddy, Soumya M., Marmon, Shoshana, Neimann, Andrea, Brusca, Samuel, Patel, Tejas, Manasson, Julia, Pamer, Eric G., Littman, Dan R., and Abramson, Steven B.
- Subjects
- *
TRANSPLANTATION of organs, tissues, etc. , *ANALYSIS of variance , *CHI-squared test , *GASTROINTESTINAL diseases , *INFLAMMATION , *MICROBIOLOGY , *PSORIASIS , *PSORIATIC arthritis , *RESEARCH funding , *STATISTICS , *T-test (Statistics) , *HLA-B27 antigen , *GENOMICS , *DATA analysis , *DATA analysis software , *DESCRIPTIVE statistics , *MANN Whitney U Test ,IMMUNE system physiology - Abstract
Objective To characterize the diversity and taxonomic relative abundance of the gut microbiota in patients with never-treated, recent-onset psoriatic arthritis (PsA). Methods High-throughput 16S ribosomal RNA pyrosequencing was utilized to compare the community composition of gut microbiota in patients with PsA (n = 16), patients with psoriasis of the skin (n = 15), and healthy, matched control subjects (n = 17). Samples were further assessed for the presence and levels of fecal and serum secretory IgA (sIgA), proinflammatory proteins, and fatty acids. Results The gut microbiota observed in patients with PsA and patients with skin psoriasis was less diverse when compared to that in healthy controls. This could be attributed to the reduced presence of several taxa. Samples from both patient groups showed a relative decrease in abundance of Coprococcus species, while samples from PsA patients were also characterized by a significant reduction in Akkermansia, Ruminococcus, and Pseudobutyrivibrio. Supernatants of fecal samples from PsA patients revealed an increase in sIgA levels and decrease in RANKL levels. Analysis of fatty acids revealed low fecal quantities of hexanoate and heptanoate in both patients with PsA and patients with psoriasis. Conclusion Patients with PsA and patients with skin psoriasis had a lower relative abundance of multiple intestinal bacteria. Although some genera were concomitantly decreased in both conditions, PsA samples had a lower abundance of reportedly beneficial taxa. This gut microbiota profile in PsA was similar to that previously described in patients with inflammatory bowel disease and was associated with changes in specific inflammatory proteins unique to this group, and distinct from that in patients with skin psoriasis and healthy controls. Thus, the role of the gut microbiome in the continuum of psoriasis-PsA pathogenesis and the associated immune response merits further study. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
29. Not your average joint: Towards precision medicine in psoriatic arthritis.
- Author
-
Castillo, Rochelle and Scher, Jose U.
- Subjects
- *
PSORIATIC arthritis , *INDIVIDUALIZED medicine , *FORECASTING - Abstract
Precision medicine, propelled by advances in multi-omics methods and analytics, aims to revolutionize patient care by using clinically-actionable molecular markers to guide diagnostic and therapeutic decisions. We describe the applications of precision medicine in risk stratification, drug selection, and treatment response prediction in psoriatic arthritis, for which targeted, personalized approaches are steadily emerging. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
30. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
- Author
-
Haberman, Rebecca, Hudesman, David, Scher, Jose U., Axelrad, Jordan, Chen, Alan, Castillo, Rochelle, Yan, Di, Izmirly, Peter, Neimann, Andrea, and Adhikari, Samrachana
- Subjects
- *
COVID-19 , *PSORIATIC arthritis - Abstract
The article explores the understanding of the implications of Covid-19 in patients with immune-mediated inflammatory disease and the effects of anticytokine and other immunosuppressive therapies needed to guide clinicians in the care of patients with psoriasis, rheumatoid arthritis and the psoriatic arthritis. It mentions that hospitalization concerns among patients with immune-mediated inflammatory disease.
- Published
- 2020
- Full Text
- View/download PDF
31. Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study.
- Author
-
Perez-Chada, Lourdes M., Haberman, Rebecca H., Chandran, Vinod, Rosen, Cheryl F., Ritchlin, Christopher, Eder, Lihi, Mease, Philip, Reddy, Soumya, Ogdie, Alexis, Merola, Joseph F., and Scher, Jose U.
- Subjects
- *
PSORIATIC arthritis , *QUALITY of life , *TERMS & phrases , *SYMPTOMS , *PSORIASIS treatment , *PSORIASIS , *CLINICAL drug trials , *RISK assessment , *RESEARCH funding , *DRUG development , *DELPHI method , *DISEASE complications ,PSYCHOLOGY of People with disabilities - Abstract
The concept of psoriatic arthritis (PsA) prevention is gaining increased interest owing to the physical limitation, poor quality of life and low remission rates that are achieved with current therapies for PsA. The psoriasis-to-PsA transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive strategies. However, identifying individuals at increased risk of developing PsA is challenging as there is no consensus on how this population should be defined. This Consensus Statement puts forward recommended terminology from the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) for defining specific subgroups of individuals during the preclinical and early clinical phases of PsA to be used in research studies. Following a three-round Delphi process, consensus was reached for three terms and definitions: 'increased risk for PsA', 'psoriasis with asymptomatic synovio-entheseal imaging abnormalities' and 'psoriasis with musculoskeletal symptoms not explained by other diagnosis'. These terms and their definitions will enable improved identification and standardization of study populations in clinical research. In the future, as increasing evidence emerges regarding the molecular and clinical features of the psoriasis-to-PsA continuum, these terms and definitions will be further refined and updated. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease.
- Author
-
Billi, Allison C., Ludwig, Jessica E., Yi Fritz, Rozic, Richard, Swindell, William R., Tsoi, Lam C., Gruzska, Dennis, Abdollahi-Roodsaz, Shahla, Xianying Xing, Diaconu, Doina, Uppala, Ranjitha, Camhi, Maya I., Klenotic, Philip A., Sarkar, Mrinal K., Husni, M. Elaine, Scher, Jose U., McDonald, Christine, Kahlenberg, J. Michelle, Midura, Ronald J., and Gudjonsson, Johann E.
- Subjects
- *
JOINT diseases , *PSORIATIC arthritis , *SKIN inflammation , *PROTEASE-activated receptors , *PATHOLOGY , *SKIN , *ANIMAL experimentation , *CELL receptors , *CELLULAR signal transduction , *BLOOD coagulation factors , *MICE - Abstract
Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease hypothesized to promote inflammation via cleavage of protease-activated receptor 1 (PAR1) and PAR2. KLK6 levels are elevated in multiple inflammatory and autoimmune conditions, but no definitive role in pathogenesis has been established. Here, we show that skin-targeted overexpression of KLK6 causes generalized, severe psoriasiform dermatitis with spontaneous development of debilitating psoriatic arthritis-like joint disease. The psoriatic skin and joint phenotypes are reversed by normalization of skin KLK6 levels and attenuated following genetic elimination of PAR1 but not PAR2. Conservation of this regulatory pathway was confirmed in human psoriasis using vorapaxar, an FDA-approved PAR1 antagonist, on explanted lesional skin from patients with psoriasis. Beyond defining a critical role for KLK6/PAR1 signaling in promoting psoriasis, our results demonstrate that KLK6/PAR1-mediated inflammation in the skin alone is sufficient to drive inflammatory joint disease. Further, we identify PAR1 as a promising cytokine-independent target in therapy of psoriasis and psoriatic arthritis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
- Author
-
Ritchlin, Christopher T, Kavanaugh, Arthur, Merola, Joseph F, Schett, Georg, Scher, Jose U, Warren, Richard B, Gottlieb, Alice B, Assudani, Deepak, Bedford-Rice, Kathy, Coarse, Jason, Ink, Barbara, and McInnes, Iain B
- Subjects
- *
PSORIATIC arthritis , *INTERLEUKINS , *RESEARCH , *INJECTIONS , *RESEARCH methodology , *MONOCLONAL antibodies , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *RANDOMIZED controlled trials , *BLIND experiment , *DOSE-effect relationship in pharmacology , *STATISTICAL sampling , *CHEMICAL inhibitors - Abstract
Background: Dual neutralisation of interleukin 17A (IL17A) and interleukin 17F (IL17F) is a potential novel therapeutic approach in psoriatic arthritis. We assessed bimekizumab, a monoclonal antibody that selectively neutralises IL17A and IL17F, in patients with active psoriatic arthritis.Methods: BE ACTIVE was a randomised, double-blind, placebo-controlled, dose-ranging phase 2b study done at 41 sites in the Czech Republic, Germany, Hungary, Poland, Russia, and the USA. Eligible patients aged 18 years or older with active adult-onset psoriatic arthritis and symptoms for at least 6 months were randomly assigned (1:1:1:1:1) to placebo, 16 mg bimekizumab, 160 mg bimekizumab, 160 mg bimekizumab with a one-off 320 mg loading dose, or 320 mg bimekizumab, which were administered as subcutaneous injections every 4 weeks for 12 weeks. After 12 weeks, patients assigned to the placebo and 16 mg bimekizumab groups were randomly reassigned (1:1) to either 160 mg or 320 mg bimekizumab, and all other patients remained on their originally assigned initial dose up to 48 weeks. Both participants and researchers were blinded to treatment allocation in the first 12 weeks, and blinded to the dose of bimekizumab thereafter. The primary endpoint was the proportion of patients with at least 50% improvement in the American College of Rheumatology response criteria at week 12, which was assessed in all patients who received at least one dose of study treatment and had a valid measurement of the primary efficacy endpoint at baseline. The trial, including all follow-up, has been completed. This trial is registered with ClinicalTrials.gov, NCT02969525.Findings: Between Oct 27, 2016, and July 16, 2018, 308 patients were screened, and 206 were randomly assigned: 42 to the placebo group, and 41 each to the four bimekizumab groups. At 12 weeks, compared with the placebo group, significantly more patients in the 16 mg bimekizumab (odds ratio [OR] 4·2 [95% CI 1·1-15·2]; p=0·032), 160 mg bimekizumab (8·1 [2·3-28·7]; p=0·0012), and 160 mg (loading dose) bimekizumab (9·7 [2·7-34·3]; p=0·0004) groups achieved an ACR50 response. At 12 weeks, 24 (57%) of 42 patients in the placebo group and 68 (41%) of the 164 patients in the bimekizumab groups reported treatment-emergent adverse events. Most of these adverse events were mild or moderate. Serious treatment-emergent adverse events occurred in nine patients, eight of whom were receiving bimekizumab. No deaths or cases of inflammatory bowel disease were reported.Interpretation: Bimekizumab doses of 16 mg and 160 mg (with or without a 320 mg loading dose) were associated with significant improvements in ACR50 compared with placebo, with an acceptable safety profile. Our results support phase 3 investigation of bimekizumab as a treatment for psoriatic arthritis.Funding: UCB Pharma. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.